Novartis Acquires Global Rights to Sironax Brain-Delivery Platform for $125 Million
The Swiss pharmaceutical group has exercised its option to acquire Sironax’s technology for transporting large therapeutic molecules across the blood-brain barrier. Novartis has exercised its exclusive option to acquire full global rights to Sironax’s…
Convergen Closes $15 Million Financing to Advance Novel Protein Degradation Therapies for Neurodegenerative Diseases
Suzhou-based Convergen has secured $15 million in Seed+ financing to advance its next-generation targeted protein degradation platform and pipeline for neurodegenerative diseases, as the Chinese biotech seeks to translate its TRIM21-based approach for…
iRegene secures another 260 million yuan in Series C+ financing to accelerate pipeline development
On July 2nd, iRegene Therapeutics announced the completion of a RMB 260 million Series C+ financing round. This round was led by Chengdu Science and Technology Venture Capital, with participation from CITIC Securities Capital, Xichuan Venture Capital,…
Xgene secured RMB 250 million in series D financing to develop novel non-opioid analgesic drugs
Recently, Xgene Pharmaceutical Inc. (“Xgene”), a company focusing on the research and development of innovative drugs in the fields of pain and neurology, completed a RMB 250 million Series D financing round. This round was jointly led by Yifeng…
XellSmart’s universal cell therapy drug for Parkinson’s disease receives Fast Track designation from the US FDA
On July 28, 2026, XellSmart Bio‘s independently developed allogeneic universal “off-the-shelf” XS411 cell therapy injection, for the treatment of Parkinson’s disease, the world’s second most prevalent neurodegenerative…